IRDiRC perspectives on the application of digital biomarkers in therapeutic development for rare diseases

IF 122.7 1区医学 Q1 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Nature Reviews. Drug Discovery Pub Date : 2024-12-16 DOI:10.1038/d41573-024-00196-z

Rajesh Krishna, Anneliene H. Jonker, Thomas Morel, Ken Sakushima, Anna M. G. Pasmooij, Daniel O’Connor

引用次数: 0

Abstract

New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential. New approaches are needed to streamline clinical trials of drugs for patients with rare diseases. Digital biomarkers offer one such approach, but several challenges must be addressed to realize their potential.

查看原文本刊更多论文

IRDiRC 关于在罕见病治疗开发中应用数字生物标记的观点

需要采用新方法来简化罕见病患者的药物临床试验。数字生物标记物就是这样一种方法，但要实现其潜力，还必须应对一些挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews. Drug Discovery 医学-生物工程与应用微生物

CiteScore

137.40

自引率

0.30%

发文量

227

期刊介绍： Nature Reviews Drug Discovery is a monthly journal aimed at everyone working in the drug discovery and development arena. Each issue includes: Highest-quality reviews and perspectives covering a broad scope. News stories investigating the hottest topics in drug discovery. Timely summaries of key primary research papers. Concise updates on the latest advances in areas such as new drug approvals, patent law, and emerging industry trends and strategies.